The strength of the interaction between T‐cell receptors (TCRs) and their ligands, peptide/major histocompatibility complex complexes (pMHCs), is one of the most frequently discussed and investigated features of T cells in immuno‐oncology today. Although there are many molecules on the surface of T cells that interact with ligands on other cells, the TCR/pMHC is the only receptor‐ligand pair that offers antigen specificity and dictates the functional response of the T cell. The strength of the TCR/pMHC interaction, along with the environment in which this interaction takes place, is key to how the T cell will respond. The TCR repertoire of T cells that interact with tumor‐associated antigens is vast, although typically of low affinity. Here, we focus on the low‐affinity interactions between TCRs from CD8+ T cells and different models used in immuno‐oncology.

中文翻译：

---

癌症免疫治疗时代的T细胞受体亲和力。

T细胞受体（TCR）与它们的配体，肽/主要组织相容性复合物（pMHCs）之间的相互作用强度是当今免疫肿瘤学中最经常讨论和研究的T细胞特征之一。尽管T细胞表面上有许多与其他细胞上的配体相互作用的分子，但TCR / pMHC是唯一提供抗原特异性并决定T细胞功能反应的受体-配体对。TCR / pMHC相互作用的强度以及发生这种相互作用的环境，是T细胞反应方式的关键。与肿瘤相关抗原相互作用的T细胞的TCR库很大，尽管亲和力通常很低。这里，